Cadrenal Therapeutics, Inc. (CVKD) - Dilution Analysis

10-Q filing | 2.9M shares outstanding

10-K filing | 2.5M shares outstanding

S-1 filing: This prospectus relates to the resale from time to time of up to an aggregate of 428,227 shares of common stock of Cadrenal Therapeutics, Inc. by the Selling Stockholders.

10-Q filing | 2.0M shares outstanding

10-Q filing | 1.8M shares outstanding

10-K filing | 1.9M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 590,001 shares of common stock by selling stockholders, including shares issuable upon exercise of warrants. The company will not receive any proceeds from the sale of these shares.

10-Q filing | 1.7M shares outstanding

8-K filing: Cadrenal Therapeutics, Inc. closed a warrant inducement agreement on November 4, 2024, receiving $4.7 million in gross proceeds from the exercise of existing warrants for 285,715 shares of common stock at $16.50 per share, and issuing new warrants to purchase 571,430 additional shares of common stock. ($4.7M proceeds)

8-K filing: On October 24, 2024, the Company sold 391,243 shares of common stock at a weighted average price of $13.15 per share, generating gross proceeds of approximately $5.1 million through its ATM facility. Following the completion of the sales under the ATM facility, the Company has 1,496,771 shares of common stock outstanding as of October 23, 2024. ($5.1M proceeds)

10-Q filing | 16.0M shares outstanding

10-Q filing | 16.0M shares outstanding

POS AM filing: This prospectus relates to the resale from time to time of up to 5,927,500 shares of Common Stock, par value $0.001 per share, of Cadrenal Therapeutics, Inc. by the selling stockholders.

S-3 filing: Cadrenal Therapeutics, Inc. files an S-3 form to offer and sell up to $100,000,000 of any combination of common stock, preferred stock, debt securities, warrants, or units. The company intends to use the net proceeds from this offering for working capital and general corporate purposes. As of March 11, 2024 there were 16,008,469 shares outstanding. The at-the-market offering is made through Wainwright.

10-K filing | 16.0M shares outstanding

10-Q filing | 12.6M shares outstanding

10-Q filing | 11.7M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 8,850,001 shares of common stock by selling stockholders, including shares purchased in a private placement and shares issuable upon the exercise of warrants.

8-K filing: Cadrenal Therapeutics, Inc. completed a private placement on July 14, 2023, issuing 1,300,000 shares of common stock, pre-funded warrants for 2,985,715 shares, and common warrants for 4,285,715 shares, raising gross proceeds of approximately $7.5 million. ($7.5M proceeds)

10-Q filing | 10.8M shares outstanding

10-K filing | 11.6M shares outstanding

8-K filing: Cadrenal Therapeutics, Inc. consummated its initial public offering of 1,400,000 shares of its common stock at $5.00 per share, generating gross proceeds of $7,000,000 and issued to the underwriters a warrant to purchase 84,000 shares of common stock at an exercise price of $6.00. ($7.0M proceeds)

S-1/A filing: This S-1/A filing is for an offering of common stock, with 1,400,000 shares being offered at an assumed price of $5.00 per share. The company estimates net proceeds of $5.7 million, or $6.7 million if the underwriters exercise their option to purchase additional shares, and intends to use the proceeds for chemistry, manufacturing and controls, research and development, and working capital.

S-1/A filing: This S-1/A filing registers an offering of common stock with Boustead Securities, LLC as underwriter, and includes warrants to purchase common stock issued to the underwriter representative.

S-1/A filing: This S-1/A filing registers for sale 1,400,000 shares of common stock at an assumed initial public offering price of $5.00 per share and warrants to purchase shares of common stock that will be issued to Boustead Securities, LLC, as the representative of the underwriters.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock underwritten by Boustead Securities, LLC. The company intends to list its common stock on the Nasdaq under the symbol "CVKD."

S-1/A filing: This S-1/A filing registers the offering of 2,000,000 shares of common stock at an assumed price of $5.00 per share, along with warrants to purchase common stock issued to the underwriter, Boustead Securities, LLC.

S-1/A filing: This S-1/A filing registers for sale 2,000,000 shares of common stock, warrants to purchase common stock issued to the underwriter, and grants the underwriter an option to purchase an additional 300,000 shares.

S-1 filing: This S-1 filing outlines a proposed offering of 2,000,000 shares of common stock along with underwriter warrants, with an option for the underwriters to purchase an additional 300,000 shares; the company intends to use the net proceeds for chemistry, manufacturing and controls, research and development and other trial preparation expenses and the balance for working capital and general corporate purposes.